



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED  
JUN 11 2002  
TECH CENTER 1600/2900

<b>Form PTO 1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>	<b>ATTY. DOCKET NO.</b> P50953D1	<b>SERIAL NO.</b> 09/853,854
	<b>APPLICANT</b> Crabb et al.	
	<b>FILING DATE</b> May 11, 2001	<b>GROUP</b> 1614

**U.S. PATENT DOCUMENTS**


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Subclass	Translation Yes   No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

1	SB-265805, A Potent New Quinolone, 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, San Diego Convention Centre, 105-F Poster Session, New Fluoroquinolones II, September 26th 1998: Abstract No. F-101 (Hannan et al.)
2	Drugline, Molecule of the Month, Drug News Perspect 11(8), October 1998, 505
3	Garau, J., The Role of Quinolones in the Treatment of Community-Acquired Pneumonia, Medicina Clinica, Vol 110, Suppl 1, 31-35 (Feb 1998)
4	Graul, A., et al., SB-265805/LB-20304a Naphthyridine Antibacterial, Drugs Future, Vol 23(11) 1199-1204 (1998)

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 9/24/03
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	